X

Drug Profile

ALXN 2030

Alternative Names: ALXN-2030

Latest Information Update: 03 Nov 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alexion AstraZeneca Rare Disease
Class Small interfering RNA
Mechanism of Action Complement C3 expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Renal transplant rejection

Most Recent Events

22 Aug 2022 Preclinical trials in Unspecified in USA (SC) before August 2022
16 Aug 2022 Phase-I clinical trials in Renal transplant rejection (In volunteers) in United Kingdom (SC, Infusion) (NCT05501717)
16 Aug 2022 Phase-I clinical trials in Renal transplant rejection (In volunteers) in United Kingdom (SC, Injection) (NCT05501717)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com